Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to -$15.3 million.

  • OptimizeRx's Income towards Parent Company rose 10853.79% to $779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 11520.25%. This contributed to the annual value of -$15.3 million for FY2024, which is 1282.02% up from last year.
  • As of FY2024, OptimizeRx's Income towards Parent Company stood at -$15.3 million, which was up 1282.02% from -$17.6 million recorded in FY2023.
  • OptimizeRx's 5-year Income towards Parent Company high stood at $378079.0 for FY2021, and its period low was -$17.6 million during FY2023.
  • Over the past 5 years, OptimizeRx's median Income towards Parent Company value was -$11.4 million (recorded in 2022), while the average stood at -$9.2 million.
  • Per our database at Business Quant, OptimizeRx's Income towards Parent Company soared by 11712.99% in 2021 and then tumbled by 312541.0% in 2022.
  • OptimizeRx's Income towards Parent Company (Annual) stood at -$2.2 million in 2020, then surged by 117.13% to $378079.0 in 2021, then plummeted by 3125.41% to -$11.4 million in 2022, then plummeted by 53.57% to -$17.6 million in 2023, then rose by 12.82% to -$15.3 million in 2024.
  • Its Income towards Parent Company stands at -$15.3 million for FY2024, versus -$17.6 million for FY2023 and -$11.4 million for FY2022.